427 related articles for article (PubMed ID: 34715057)
21. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
Koné-Paut I; Tellier S; Belot A; Brochard K; Guitton C; Marie I; Meinzer U; Cherqaoui B; Galeotti C; Boukhedouni N; Agostini H; Arditi M; Lambert V; Piedvache C
Arthritis Rheumatol; 2021 Jan; 73(1):151-161. PubMed ID: 32779863
[TBL] [Abstract][Full Text] [Related]
22. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
23. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K; Ishii M; Iemura M; Akagi T; Kato H
Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
[TBL] [Abstract][Full Text] [Related]
24. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[TBL] [Abstract][Full Text] [Related]
25. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
Baek JS; Yu JJ; Kim MJ; You J; Jun HO; Kim YH; Ko JK
Pediatr Rheumatol Online J; 2018 Dec; 16(1):83. PubMed ID: 30594188
[TBL] [Abstract][Full Text] [Related]
26. Procalcitonin levels predicting the infliximab response of immunoglobulin resistant Kawasaki disease.
Nakashima Y; Nanishi E; Yamamura K; Uike K; Terashi E; Hirata Y; Nagata H; Morihana E; Tanaka T; Honjo S; Takada H; Ohga S
Cytokine; 2019 Feb; 114():26-31. PubMed ID: 30583086
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
28. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
Tanaka A; Inoue M; Hoshina T; Koga H
J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease.
He L; Liu F; Yan W; Huang M; Huang M; Xie L; Guo Y; Xu X; Chu C; Wu L; Liang X; Sun S; Wang F; Zhao L; Zhao Q; Ma X; Xie L; Huang G
Pediatr Int; 2021 Jul; 63(7):757-763. PubMed ID: 33600060
[TBL] [Abstract][Full Text] [Related]
30. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[TBL] [Abstract][Full Text] [Related]
31. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
32. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ; Jung JW
Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
[TBL] [Abstract][Full Text] [Related]
35. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
Singh S; Sharma D; Suri D; Gupta A; Rawat A; Rohit MK
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group
Lancet Child Adolesc Health; 2024 Mar; 8(3):190-200. PubMed ID: 38272046
[TBL] [Abstract][Full Text] [Related]
37. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
Mori M; Hara T; Kikuchi M; Shimizu H; Miyamoto T; Iwashima S; Oonishi T; Hashimoto K; Kobayashi N; Waki K; Suzuki Y; Otsubo Y; Yamada H; Ishikawa C; Kato T; Fuse S
Sci Rep; 2018 Jan; 8(1):1994. PubMed ID: 29386515
[TBL] [Abstract][Full Text] [Related]
38. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
39. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
40. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
